Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen ‘welcomes' EC decision to revoke CMAs for generic versions of Tecfidera
07:49am, Tuesday, 19'th Dec 2023
Biogen Inc. BIIB, +0.89% said Tuesday that the European Commission has revoked the centralized marketing authorizations for generic versions of the biotechnology company's multiple sclerosis treatment
Wells Fargo's top pharma picks for 2024
05:33pm, Friday, 15'th Dec 2023
Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
07:43pm, Thursday, 14'th Dec 2023
Mental health has been one of the hot topics in the medical industry over the past few years. Widespread awareness was brought to the public eye during the COVID-19 pandemic as people in prolonged loc
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
10:32am, Monday, 11'th Dec 2023
The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.
2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond
01:52pm, Saturday, 09'th Dec 2023
Aurora Cannabis' latest financial results were decent, but that doesn't make up for years of poor performance. Biogen has proven it can be a highly innovative biotech, but it will take more than that
Why Is Biogen Inc. (BIIB) Up 6.4% Since Last Earnings Report?
12:48pm, Friday, 08'th Dec 2023
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?
Alzheimer's Disease Drug Development: Another Lost Year
03:58am, Tuesday, 05'th Dec 2023
Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of
Biogen: LAQEMBI's $10 Billion Potential
03:00pm, Wednesday, 29'th Nov 2023
Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks;
Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript)
12:12pm, Tuesday, 28'th Nov 2023
Biogen Inc. (NASDAQ:BIIB ) Evercore ISI 6th Annual HealthCONx Conference November 28, 2023 9:10 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Umer Raffat
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
06:50am, Friday, 10'th Nov 2023
There's now more than one medicine on the market to treat Alzheimer's disease. Safety and efficacy will be the two major areas of future competition.
Biogen lowers full-year earnings guidance, 3Q revenue beats expectations
01:24pm, Wednesday, 08'th Nov 2023
Biogen Inc (NASDAQ:BIIB) revised its full-year earnings guidance downward due to acquisition-related costs following the company's $7.3 billion bid for Reata Pharmaceuticals in July. The firm said it
Biogen Inc. (BIIB) Q3 2023 Earnings Call Transcript
01:03pm, Wednesday, 08'th Nov 2023
Biogen Inc. (NASDAQ:BIIB ) Q3 2023 Results Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Chuck Triano - Head of Investor Relations Christopher Viehbacher - President and Ch
Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View
12:01pm, Wednesday, 08'th Nov 2023
Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact of dilution from the Reata acquisition.
Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatment
07:10am, Wednesday, 08'th Nov 2023
Biogen Inc. BIIB, -1.21% on Wednesday reported third quarter results that topped analyst estimates, even as it navigates a complex launch of its new Alzheimer's treatment Leqembi.
Biogen cuts annual profit forecast on persistent higher costs
07:03am, Wednesday, 08'th Nov 2023
Biogen cut its annual profit forecast below Wall Street expectations on Wednesday, on rising costs related to the recent acquisition of rare disease drugmaker Reata Pharmaceuticals and the launch of i
